[go: up one dir, main page]

GB202319149D0 - Antibody - Google Patents

Antibody

Info

Publication number
GB202319149D0
GB202319149D0 GBGB2319149.7A GB202319149A GB202319149D0 GB 202319149 D0 GB202319149 D0 GB 202319149D0 GB 202319149 A GB202319149 A GB 202319149A GB 202319149 D0 GB202319149 D0 GB 202319149D0
Authority
GB
United Kingdom
Prior art keywords
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2319149.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kbio Holdings Ltd
Original Assignee
Kbio Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kbio Holdings Ltd filed Critical Kbio Holdings Ltd
Priority to GBGB2319149.7A priority Critical patent/GB202319149D0/en
Publication of GB202319149D0 publication Critical patent/GB202319149D0/en
Priority to PCT/US2024/060121 priority patent/WO2025129060A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
GBGB2319149.7A 2023-12-14 2023-12-14 Antibody Ceased GB202319149D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2319149.7A GB202319149D0 (en) 2023-12-14 2023-12-14 Antibody
PCT/US2024/060121 WO2025129060A1 (en) 2023-12-14 2024-12-13 Anti-lilrb2 antibodies and their use in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2319149.7A GB202319149D0 (en) 2023-12-14 2023-12-14 Antibody

Publications (1)

Publication Number Publication Date
GB202319149D0 true GB202319149D0 (en) 2024-01-31

Family

ID=89662558

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2319149.7A Ceased GB202319149D0 (en) 2023-12-14 2023-12-14 Antibody

Country Status (2)

Country Link
GB (1) GB202319149D0 (en)
WO (1) WO2025129060A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728318A2 (en) * 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antibodies for lilrb2
JP2022501428A (en) * 2018-09-17 2022-01-06 アイカーン スクール オブ メディスン アット マウント シナイ Anti-LILRB2 antibody and method of its use
EP4304648A1 (en) * 2021-03-09 2024-01-17 Jounce Therapeutics, Inc. Methods for the treatment of cancer

Also Published As

Publication number Publication date
WO2025129060A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
GB2614651B (en) Antibodies
GB202015115D0 (en) ZIP12 Antibody
IL324435A (en) Anti-il1rap antibodies
GB202105933D0 (en) Anti-IL1rap antibody
GB202309981D0 (en) Antibody
GB2627309B (en) Antibodies
IL317231A (en) Anti-bcma antibodies
GB202304512D0 (en) Antibodies
GB202217924D0 (en) Antibodies
GB202204159D0 (en) Antibodies
GB202319122D0 (en) Antibody
GB202319149D0 (en) Antibody
IL315568A (en) Zip12 antibody
GB202206195D0 (en) Antibody
IL325202A (en) Anti-fibril antibodies
IL320725A (en) Anti-beta-catenin antibodies
GB202400120D0 (en) Anti-pgdh antibodies
GB202319255D0 (en) Anti-UNC5C antibodies
GB202318820D0 (en) Antibodies
GB202317371D0 (en) Anti-unc5c antibodies
GB202317192D0 (en) Anti-agr2 antibodies
GB202317189D0 (en) Anti-AGR2 antibodies
GB202317188D0 (en) Anti-AGR2 antibodies
GB202317187D0 (en) Anti-AGR2 antibodies
GB202316016D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)